Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
AVROBIO Inc
NASDAQ AVRO
Data sourced from
and
and
AVROBIO Inc Free Cash Flow Margin 5 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024
AVROBIO Inc Free Cash Flow Margin 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The Free Cash Flow Margin measures the percentage of revenue that is converted into free cash flow. It indicates the company's ability to generate cash flow from its operations after accounting for capital expenditures. A higher margin suggests better cash flow generation and potential for reinvestment or distribution to shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: AVRO
| CEO | Mr. Geoff MacKay BSc |
| IPO Date | June 21, 2018 |
| Location | United States |
| Headquarters | Building 300, Cambridge, MA, United States, 02139 |
| Employees | 13 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key trends
Similar companies
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email